Track topics on Twitter Track topics that are important to you
This study is the third in a series using the MenB vaccine from the National Institute of Public Health in Norway (NIPH). The vaccine was first made in response to a high incidence of disease using the 44/76 strain which was resopnsible for most of the disease there. The VEC did the first study, MNB1, using this vaccine. Since then the NIPH has formed a commercial partnership with Chiron Vaccines and has reformulated the vaccine using the NZ98/254 MenB strain for use in New Zealand.
The vaccine was first produced at NIPH facilties and it was this vaccine that was used in our second study, MNB2. The current study, MNB3, will use the NZ98/254 MenB vaccine but from Chiron facilities where production has been scaled up in order to provide enough doses for the national immunisation campaign that is ongoing in New Zealand.
Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Neisseria Meningitidis Serogroup B
Meningococcal B Vaccine NZ
University of Sheffield Medical School
Health Protection Agency
Published on BioPortfolio: 2014-07-23T21:30:02-0400
The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccina...
This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC...
This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine, this s...
The purpose of this study is to investigate the immunogenicity, safety and tolerability of a new vaccine that might prevent meningococcal B disease. The study will be conducted in healthy ...
The proposed study is aimed to assess the immunogenicity, safety and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vacci...
Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal ser...
The bacterial pathogen Neisseria meningitidis is able to escape the currently available capsule-based vaccines by undergoing capsule switching. In this study, we investigated whether capsule switching...
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in...
Neisseria meningitidis constitutes a major public health problem among countries in the African meningitis belt. Following regional vaccination campaigns for serogroup A and subsequent increases in pr...
Meningococcal infection starts with colonisation of the upper respiratory tract. Mucosal immunity is important for protection against acquisition and subsequent meningococcal carriage. In this study, ...
Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal disease in Western Europe and the United States in the first half of the 20th century. They continue to be a major cause of disease in Asia and Africa, and especially localized epidemics in Sub-Sahara Africa.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
Strains of Neisseria meningitidis which, in the United States, causes disease in mostly adults and the elderly. Serogroup Y strains are associated with PNEUMONIA.
Strains of Neisseria meningitidis found mostly in Africa.
Strains of Neisseria meningitidis responsible for most sporadic cases in teenagers and almost all outbreaks of disease in this age group. These strains are less common in infants.
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...